Multidisciplinary Cancer Investigation
Fri, Apr 11, 2025
[Archive]
Volume 7, Issue 4 (Multidisciplinary Cancer Investigation 2023)
Multidiscip Cancer Investig 2023, 7(4): 16-24 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Yarmohammadi H, Shahrabi Farahani M, Soltanipur M, Mahdavi Anari S F, Sheikhi Z. A Scoping Review of Lymphedema in Iran. Multidiscip Cancer Investig 2023; 7 (4) :16-24
URL: http://mcijournal.com/article-1-386-en.html
URL: http://mcijournal.com/article-1-386-en.html
Hossein Yarmohammadi1 
, Mohammad Shahrabi Farahani1 , Masood Soltanipur1 , Seyed Fatah Mahdavi Anari2 , Zahra Sheikhi3
, Mohammad Shahrabi Farahani1 , Masood Soltanipur1 , Seyed Fatah Mahdavi Anari2 , Zahra Sheikhi3
1- Medical Students Research Committee, Shahed University, Tehran, Iran
2- Department of Dermatology, Shiraz University of Medical Sciences, Shiraz, Iran
3- Quality of Life Department, Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran ,dr.shaikhi88@gmail.com
2- Department of Dermatology, Shiraz University of Medical Sciences, Shiraz, Iran
3- Quality of Life Department, Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran ,
Abstract: (453 Views)
Despite significant publications in cancer survivorship, a scoping review was needed to picture the current interests and achievements of lymphedema research, as well as gaps and opportunities in Iran. Databases such as PubMed, Scopus, Google Scholar, and Persian databases (SID and MagIran) were searched to collect data. The main topics were divided into four major categories: treatment, prevention, diagnosis, and complications. Moreover, the level of evidence (LoE) was determined based on the Oxford Criteria 2009. After screening, of the 105 articles included in this study, 68 (64.7%) were English. The number of published articles increased to 14 (13.3%) and 56 (53.3%) during the first (2000-2009) and second (2010-2019) decades, respectively. In addition, 32 (30.4%) articles were published during 2020-2023. The majority of articles were related to breast cancer-related lymphedema (64.7%) and interventional trials (46.6%, 18.1% were RCTs), with the LoE of 1 and 2 (44.7%). The topic of treatment was the most investigated topic among the included articles (51.6%), and valuable studies were recently published about the prediction of lymphedema using machine learning and artificial intelligence. This scoping review showed an increasing trend of lymphedema research in Iran during the past years. Most of the research output is focused on the treatment of breast cancer-related lymphedema (BCRL) and studies on animal models and epidemiology of lymphedema are the main gaps in this field.
Select article type: Review Article |
Subject:
Health Services, Quality of Life and Outcomes
Received: 2023/02/20 | Accepted: 2023/09/8 | ePublished: 2023/10/17
Received: 2023/02/20 | Accepted: 2023/09/8 | ePublished: 2023/10/17
References
1. Manrique OJ, Bustos SS, Ciudad P, Adabi K, Chen WF, Forte AJ, et al. Overview of Lymphedema for Physicians and Other Clinicians: A Review of Fundamental Concepts. Mayo Clin Proc. 2022;97(10):1920-35. DOI: 10.1016/j. mayocp.2020.01.006 PMID: 32829905. [DOI:10.1016/j.mayocp.2020.01.006] [PMID]
2. Cromwell EA, Schmidt CA, Kwong KT, Pigott DM, Mup¬fasoni D, Biswas G, et al. The global distribution of lym¬phatic filariasis, 2000-18: a geospatial analysis. Lancet Glob Health. 2020;8(9):e1186-e94. DOI: 10.1016/S2214- 109X(20)30286-2 PMID: 32827480.
3. Bernas M, Thiadens SRJ, Stewart P, Granzow J. Second¬ary lymphedema from cancer therapy. Clin Exp Metastasis. 2022;39(1):239-47. DOI: 10.1007/s10585-021-10096-w PMID: 33950413. [DOI:10.1007/s10585-021-10096-w] [PMID]
4. Duhon BH, Phan TT, Taylor SL, Crescenzi RL, Rutkowski JM. Current Mechanistic Understandings of Lymphedema and Lipedema: Tales of Fluid, Fat, and Fibrosis. Int J Mol Sci. 2022;23(12). DOI: 10.3390/ijms23126621 PMID: 35743063. [DOI:10.3390/ijms23126621] [PMID] []
5. Azhar SH, Lim HY, Tan BK, Angeli V. The Unre¬solved Pathophysiology of Lymphedema. Front Physiol. 2020;11:137. DOI: 10.3389/fphys.2020.00137 PMID: 32256375. [DOI:10.3389/fphys.2020.00137] [PMID] []
6. Zhang YD, Zhang X, Wang XY, Han DM, Du JS. Visual analysis of global research output of lymphedema based on bibliometrics. Front Oncol. 2022;12:926237. DOI: 10.3389/fonc.2022.926237 PMID: 35992843. [DOI:10.3389/fonc.2022.926237] [PMID] []
7. Torgbenu E, Luckett T, Buhagiar MA, Phillips JL. Guide¬lines Relevant to Diagnosis, Assessment, and Manage¬ment of Lymphedema: A Systematic Review. Adv Wound Care (New Rochelle). 2023;12(1):15-27. DOI: 10.1089/ wound.2021.0149 PMID: 35196892. [DOI:10.1089/wound.2021.0149] [PMID]
8. Arksey H, O'Malley L. Scoping studies: towards a method¬ological framework. Int J Soc Res Methodol. 2005;8(1):19- 32. DOI: 10.1080/1364557032000119616. [DOI:10.1080/1364557032000119616]
9. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann In¬tern Med. 2018;169(7):467-73. DOI: 10.7326/M18-0850 PMID: 30178033. [DOI:10.7326/M18-0850] [PMID]
10. Heneghan C. EBM resources on the new CEBM web¬site. Evid Based Med. 2009;14(3):67. DOI: 10.1136/ ebm.14.3.67 PMID: 19483016. [DOI:10.1136/ebm.14.3.67] [PMID]
11. Yarmohammadi H, Rooddehghan A, Soltanipur M, Sarafraz A, Mahdavi Anari SF. Healthcare Practitioners' Knowledge of Lymphedema. Int J Vasc Med. 2021;2021:3806150. DOI: 10.1155/2021/3806150 PMID: 35003807. [DOI:10.1155/2021/3806150] [PMID] []
12. Fadhil M, Singh R, Havas T, Jacobson I. Systematic review of head and neck lymphedema assessment. Head Neck. 2022;44(10):2301-15. DOI: 10.1002/hed.27136 PMID: 35818729. [DOI:10.1002/hed.27136] [PMID]
13. Vignes S. Genital Lymphedema after Cancer Treatment: A Narrative Review. Cancers (Basel). 2022;14(23). DOI: 10.3390/cancers14235809 PMID: 36497291. [DOI:10.3390/cancers14235809] [PMID] []
14. Al-Sakkaf AM, Masia J, Auladell-Rispau A, Shamardal AI, Vasconcello-Castillo L, Sola I, et al. Evidence Mapping of the Treatments for Breast Cancer-related Lymphedema. Plast Reconstr Surg Glob Open. 2022;10(1):e4045. DOI: 10.1097/GOX.0000000000004045 PMID: 35070599. [DOI:10.1097/GOX.0000000000004045] [PMID] []
15. Walker J, Tanna S, Roake J, Lyons O. A systematic re¬view of pharmacologic and cell-based therapies for treat¬ment of lymphedema (2010-2021). J Vasc Surg Venous Lymphat Disord. 2022;10(4):966-75 e1. DOI: 10.1016/j. jvsv.2021.09.004 PMID: 34587525. [DOI:10.1016/j.jvsv.2021.09.004] [PMID]
16. Mahmood D, Ahmad A, Sharif F, Arslan SA. Clinical ap¬plication of low-level laser therapy (Photo-biomodulation therapy) in the management of breast cancer-related lymph¬edema: a systematic review. BMC Cancer. 2022;22(1):937. DOI: 10.1186/s12885-022-10021-8 PMID: 36042421. [DOI:10.1186/s12885-022-10021-8] [PMID] []
17. Sheikhi-Mobarakeh Z, Yarmohammadi H, Mokhatri-Hes¬ari P, Fahimi S, Montazeri A, Heydarirad G. Herbs as old potential treatments for lymphedema management: A sys¬tematic review. Complement Ther Med. 2020;55:102615. DOI: 10.1016/j.ctim.2020.102615 PMID: 33221590. [DOI:10.1016/j.ctim.2020.102615] [PMID]
18. Executive C. The Diagnosis and Treatment of Periph¬eral Lymphedema: 2016 Consensus Document of the International Society of Lymphology. Lymphology. 2016;49(4):170-84. PMID: 29908550.
19. Lurie F, Malgor RD, Carman T, Dean SM, Iafrati MD, Kh¬ilnani NM, et al. The American Venous Forum, American Vein and Lymphatic Society and the Society for Vascular Medicine expert opinion consensus on lymphedema diag¬nosis and treatment. Phlebology. 2022;37(4):252-66. DOI: 10.1177/02683555211053532 PMID: 35258350. [DOI:10.1177/02683555211053532] [PMID] []
20. Hendrickx AA, Kuthe SW, van der Schans CP, Krijnen WP, Moues-Vink CM, Damstra RJ. Early Referral for Breast-Cancer-Related Lymphedema: Do We Follow the Evidence? A Two-Year Prospective Multicenter Cohort Study. Cancers (Basel). 2022;14(23). DOI: 10.3390/can¬cers14236016 PMID: 36497495. [DOI:10.3390/cancers14236016] [PMID] []
21. Koelmeyer LA, Borotkanics RJ, Alcorso J, Prah P, Winch CJ, Nakhel K, et al. Early surveillance is associated with less incidence and severity of breast cancer-related lymph¬edema compared with a traditional referral model of care. Cancer. 2019;125(6):854-62. DOI: 10.1002/cncr.31873 PMID: 30521080. [DOI:10.1002/cncr.31873] [PMID] []
22. Finkelstein ER, Ha M, Hanwright P, Ngaage LM, Yoon JS, Liang F, et al. A review of American insurance coverage and criteria for conservative management of lymphedema. J Vasc Surg Venous Lymphat Disord. 2022;10(4):929-36. DOI: 10.1016/j.jvsv.2022.03.008 PMID: 35364303. [DOI:10.1016/j.jvsv.2022.03.008] [PMID]
23. Dean LT, Moss SL, Ransome Y, Frasso-Jaramillo L, Zhang Y, Visvanathan K, et al. "It still affects our economic sit¬uation": long-term economic burden of breast cancer and lymphedema. Support Care Cancer. 2019;27(5):1697-708. DOI: 10.1007/s00520-018-4418-4 PMID: 30121786. [DOI:10.1007/s00520-018-4418-4] [PMID] []
24. Schaverien MV, Coroneos CJ. Surgical Treatment of Lymphedema. Plast Reconstr Surg. 2019;144(3):738-58. DOI: 10.1097/PRS.0000000000005993 PMID: 31461041. [DOI:10.1097/PRS.0000000000005993] [PMID]
25. Schaverien MV, Baumann DP, Selber JC, Chang EI, Hana¬sono MM, Chu C, et al. Building a Multidisciplinary Com¬prehensive Academic Lymphedema Program. Plast Re¬constr Surg Glob Open. 2020;8(3):e2670. DOI: 10.1097/ GOX.0000000000002670 PMID: 32537334. [DOI:10.1097/GOX.0000000000002670] [PMID] []
26. He J, Baxter SL, Xu J, Xu J, Zhou X, Zhang K. The prac¬tical implementation of artificial intelligence technologies in medicine. Nat Med. 2019;25(1):30-6. DOI: 10.1038/ s41591-018-0307-0 PMID: 30617336. [DOI:10.1038/s41591-018-0307-0] [PMID] []
27. Pan LC, Wu XR, Lu Y, Zhang HQ, Zhou YL, Liu X, et al. Artificial intelligence empowered digital health technolo¬gies in cancer survivorship care: A scoping review. Asia Pac J Oncol Nurs. 2022;9(12):100127. DOI: 10.1016/j.ap¬jon.2022.100127 PMID: 36176267. [DOI:10.1016/j.apjon.2022.100127] [PMID] []
28. Eldaly AS, Avila FR, Torres-Guzman RA, Maita K, Garcia JP, Serrano LP, et al. Artificial intelligence and lymphede¬ma: State of the art. J Clin Transl Res. 2022;8(3):234-42. PMID: 35813896.
29. Ogino R, Yokooji T, Hayashida M, Suda S, Yamakawa S, Hayashida K. Emerging Anti-Inflammatory Pharmacother¬apy and Cell-Based Therapy for Lymphedema. Int J Mol Sci. 2022;23(14). DOI: 10.3390/ijms23147614 PMID: 35886961. [DOI:10.3390/ijms23147614] [PMID] []
30. Hsu JF, Yu RP, Stanton EW, Wang J, Wong AK. Cur¬rent Advancements in Animal Models of Postsurgical Lymphedema: A Systematic Review. Adv Wound Care (New Rochelle). 2022;11(8):399-418. DOI: 10.1089/ wound.2021.0033 PMID: 34128396. [DOI:10.1089/wound.2021.0033] [PMID] []
31. Sheikhi-Mobarakeh Z, Yarmohammadi H, Montazeri A. The Impact Of Covid-19 Pandemic On Lymphedema Fol¬low-Ups In The Lymphedema Clinic At Motamed Cancer Institute. Multidiscip Cancer Investig. 2021;5(4). DOI: 10.30699/mci.5.4.460-2 [DOI:10.30699/mci.5.4.460-2]
32. Martinez-Jaimez P, Fuster Linares P, Piller N, Masia J, Ya¬mamoto T, Lopez-Montoya L, et al. Multidisciplinary pre¬ventive intervention for breast cancer-related lymphede¬ma: An international consensus. Eur J Cancer Care (Engl). 2022;31(6):e13704. DOI: 10.1111/ecc.13704 PMID: 36113999. [DOI:10.1111/ecc.13704] [PMID]
33. Papadopoulou MC, Tsiouri I, Salta-Stankova R, Drakou A, Rousas N, Roussaki-Schulze AV, et al. Multidisciplinary lymphedema treatment program. Int J Low Extrem Wounds. 2012;11(1):20-7. DOI: 10.1177/1534734612438436 PMID: 22336900. [DOI:10.1177/1534734612438436] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
